MoFo News Item

MoFo Advises Astellas in Acquisition of Partner Mitobridge

04 Dec 2017

Morrison & Foerster is advising Tokyo, Japan-based Astellas Pharma Inc. in the acquisition of its partner Mitobridge, Inc., a biotechnology company that focuses on mitochondrial therapeutics. Astellas is exercising its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing an R&D collaboration. Astellas will pay an upfront fee of $225 million and Mitobridge will be eligible for additional payments that total up to $225 million. The closing of the deal is subject to customary regulatory approvals, and is expected to be finalized in the next several weeks.

The MoFo team advising Astellas includes partners Stephen Thau (Northern Virginia) and Rufus Pichler (San Francisco), as well as Northern Virginia associates Tom Randall and Lucas Barta. Jeff Jaeckel, co-chair of the firm’s Global Antitrust Law Practice Group, and Washington, DC associate Kerry Jones are also assisting on HSR matters. Morrison & Foerster represented Astellas in its initial investment and the original and amended partnership agreement.

For more information, see the related press release.

Select media coverage:

  • Daily Journal: Dealmakers (December 12, 2017)


Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.